secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2024-01-18T23:59:59+00:00
Accession:  0001493152-24-002896
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TenX Keane shareholders OK extension to Nov 18, 2024; $24.9M redeemed
---------------------------------------------------------------------

- Shareholders approved amendment to extend combination deadline from Jan 18, 2024 to Nov 18, 2024 via up to 8 monthly extensions.
- Sponsor/Citius Pharma deposited $200k into trust for the first 3-month extension to April 18, 2024.
- 2,287,923 ordinary shares redeemed at ~$10.90/share, removing $24.9M from trust account.
- Company issued $200k non-interest promissory note to Citius Pharma; due at merger close if trust balance ≥ $2M.
- Ratification of Marcum LLP as independent auditor for FY 2023 approved unanimously.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000149315224002896/0001493152-24-002896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000149315224002896/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-002896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer